Aduro Biotech, Inc. (NASDAQ:ADRO) received a $18.00 price target from investment analysts at HC Wainwright in a note issued to investors on Wednesday. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 126.42% from the stock’s current price.
Other research analysts also recently issued reports about the stock. Oppenheimer Holdings, Inc. began coverage on shares of Aduro Biotech in a research note on Monday. They issued a “buy” rating and a $15.00 target price for the company. BidaskClub upgraded shares of Aduro Biotech from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. William Blair restated an “outperform” rating on shares of Aduro Biotech in a research note on Monday, October 2nd. Zacks Investment Research upgraded shares of Aduro Biotech from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a research note on Tuesday, July 4th. Finally, Cowen and Company began coverage on shares of Aduro Biotech in a research note on Tuesday, July 18th. They issued an “outperform” rating for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $19.14.
Aduro Biotech (NASDAQ ADRO) opened at 7.95 on Wednesday. Aduro Biotech has a 12 month low of $7.95 and a 12 month high of $15.52. The firm has a 50-day moving average of $10.07 and a 200 day moving average of $10.84. The stock’s market cap is $593.17 million.
Aduro Biotech (NASDAQ:ADRO) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.02). Aduro Biotech had a negative return on equity of 43.92% and a negative net margin of 609.58%. The business had revenue of $5.90 million for the quarter, compared to analysts’ expectations of $3.98 million. During the same quarter in the prior year, the firm earned $0.03 earnings per share. Aduro Biotech’s quarterly revenue was down 84.9% compared to the same quarter last year. Analysts anticipate that Aduro Biotech will post ($1.36) EPS for the current year.
TRADEMARK VIOLATION WARNING: This piece was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2017/11/01/hc-wainwright-reiterates-18-00-price-target-for-aduro-biotech-inc-adro.html.
In other Aduro Biotech news, VP Blaine Templeman sold 2,884 shares of the stock in a transaction on Monday, September 18th. The shares were sold at an average price of $11.20, for a total transaction of $32,300.80. Following the transaction, the vice president now directly owns 58,834 shares in the company, valued at approximately $658,940.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Dirk G. Brockstedt sold 10,000 shares of the stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $10.59, for a total transaction of $105,900.00. The disclosure for this sale can be found here. Insiders sold 342,745 shares of company stock valued at $3,956,397 over the last 90 days. Insiders own 6.60% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Legal & General Group Plc boosted its stake in Aduro Biotech by 11.2% during the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock valued at $118,000 after acquiring an additional 1,043 shares during the last quarter. Fox Run Management L.L.C. bought a new position in Aduro Biotech during the 3rd quarter valued at $127,000. Parametric Portfolio Associates LLC boosted its stake in Aduro Biotech by 15.9% during the 1st quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 2,119 shares during the last quarter. Tudor Investment Corp ET AL boosted its stake in Aduro Biotech by 34.8% during the 1st quarter. Tudor Investment Corp ET AL now owns 15,436 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 3,984 shares during the last quarter. Finally, Voya Investment Management LLC boosted its stake in Aduro Biotech by 15.3% during the 2nd quarter. Voya Investment Management LLC now owns 18,935 shares of the biotechnology company’s stock valued at $216,000 after acquiring an additional 2,515 shares during the last quarter. Hedge funds and other institutional investors own 35.24% of the company’s stock.
Aduro Biotech Company Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
What are top analysts saying about Aduro Biotech Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aduro Biotech Inc. and related companies.